Cogent Biosciences Inc - Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
Cogent Biosciences Inc——將Bezuclastinib加入舒尼替尼的總體耐受性仍然良好,安全性令人鼓舞
Cogent Biosciences Inc - Addition of Bezuclastinib to Sunitinib Continues to Be Generally Well-Tolerated With an Encouraging Safety Profile
Cogent Biosciences Inc——將Bezuclastinib加入舒尼替尼的總體耐受性仍然良好,安全性令人鼓舞
譯文內容由第三人軟體翻譯。